Back Login for AI Analysis

    DSGN (STOCKS)

    Design Therapeutics, Inc. Common Stock

    $14.390000
    -0.270000 (-1.84%)
    Prev close: $14.660000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Biotechnology
    CEO
    Pratik Shah
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $1,035.36M
    Employees
    55
    P/E (TTM)
    -12.42
    P/B (TTM)
    4.54
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Jun 2026)
    Revenues $0.00
    Operating Expenses $79.36M
    Research and Development $58.78M
    Other Operating Expenses $20.58M
    Operating Income/Loss -$79.36M
    Income/Loss From Continuing Operations After Tax -$70.80M
    Income/Loss From Continuing Operations Before Tax -$70.80M
    Net Income/Loss -$70.80M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$70.80M
    Net Income/Loss Available To Common Stockholders, Basic -$70.80M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$1.18
    Diluted Earnings Per Share -$1.18
    Basic Average Shares 119,397,269
    Diluted Average Shares 119,397,269
    Assets $215.13M
    Current Assets $212.01M
    Cash $207.40M
    Prepaid Expenses $2.83M
    Other Current Assets $1.78M
    Noncurrent Assets $3.12M
    Fixed Assets $694.00K
    Other Non-current Assets $2.42M
    Liabilities $13.27M
    Current Liabilities $11.24M
    Accounts Payable $3.14M
    Wages $2.79M
    Other Current Liabilities $5.31M
    Noncurrent Liabilities $2.03M
    Equity $201.86M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $201.86M
    Liabilities And Equity $215.13M
    Net Cash Flow From Operating Activities -$55.08M
    Net Cash Flow From Operating Activities, Continuing -$55.08M
    Net Cash Flow From Investing Activities $2.39M
    Net Cash Flow From Investing Activities, Continuing $2.39M
    Net Cash Flow From Financing Activities $45.89M
    Net Cash Flow From Financing Activities, Continuing $45.89M
    Net Cash Flow -$6.80M
    Net Cash Flow, Continuing -$6.80M
    Comprehensive Income/Loss -$71.87M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$71.87M
    Other Comprehensive Income/Loss -$18.07M